The flu treatment Relenza looks unlikely to be made available on the National
Health Service in Britain. As 91av went to press, the National
Institute for Clinical Excellence was thought to have advised against releasing
the drug, which limits symptoms and hastens recovery. Richard Sykes, chairman of
Glaxo Wellcome, the drug’s maker, is incensed. Yet a company data sheet prepared
in August states that the drug has yet to be shown to work in chronically ill or
immunocompromised patients, who are most at risk from complications of the
flu.
More from 91av
Explore the latest news, articles and features
Popular articles
Trending 91av articles
1
Is stem cell therapy about to transform medicine and reverse ageing?
2
Largest-ever octopus was great white shark of invertebrate predators
3
The monstrous number sequences that break the rules of mathematics
4
Symptoms of early dementia reversed by bespoke treatment plans
5
Gravity's strength measured more reliably than ever before
6
Why your opinion of used electric vehicles is probably wrong
7
Fermat's Last Theorem: still a must-read about a 350-year maths secret
8
QBox theory may offer glimpse of reality deeper than quantum realm
9
Why the right kind of stress is crucial for your health and happiness
10
We might finally know how to use quantum computers to boost AI
